We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Almac Launches New Histone Reagents Catalogue and Custom Synthesis Service
Product News

Almac Launches New Histone Reagents Catalogue and Custom Synthesis Service

Almac Launches New Histone Reagents Catalogue and Custom Synthesis Service
Product News

Almac Launches New Histone Reagents Catalogue and Custom Synthesis Service


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Almac Launches New Histone Reagents Catalogue and Custom Synthesis Service"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Almac has announced the launch of a new reagent offering based on the provision of homogeneous full length histones with defined patterns of modification.

The histone reagents will prove a highly valuable tool for researchers seeking to prosecute key drug targets in the field of epigenetics.

Almac’s unique array of platform technologies for the chemical synthesis of proteins, enable the provision of pure full-length natural histones containing a wide variety of post-translational modifications at any specified site(s) within the protein.

The reagents are set to be offered through a catalogue of modified histones and additionally as a custom synthesis service to meet bespoke customer demands.

Almac believes this will provide the epigenetic research community with a unique source of enabling research tools.

The modified histone reagent provision complements Almac’s growing range of FLEXYTE® FLT assays for epigenetic targets.

‘This is a first class example of how Almac can harness its unique protein synthesis capability to provide a much needed source of tools to the epigenetic research field.  I am delighted that we are able to offer such capabilities.’ commented Dr Charles Shields, Vice President of Peptide and Protein Technologies at Almac.

Advertisement